CEBPA and leukemia: R-2-Hydroxyglutarate (R-2HG) directly binds to the FTO (which participates in the m6A process) and inhibits its activity, thereby reducing the m6A modification and stability of c-MYC and CEBPA in the 5′-UTR and coding regions, leading to apoptosis of leukemia cells [83].